Learn more about our latest achievements, product updates, and our involvement in research projects
Monsenso has announced that the board of Directors has decided to call for an Extraordinary General Meeting on January 29th, 2021, where two new members are proposed to be elected for the board.
Monsenso expands in the Middle East with new million-kroner agreement with global pharmaceutical company
Monsenso A / S is establishing an office in the UK to support the growth plan and is hiring Michelle Woolley as Area Sales Manager.
Monsenso and Empano enter a partnership to help unemployed people coping with stress and depression get back into the labor force.
Following a year-long collaboration, Monsenso signs a three-year +10 mio DKK agreement with a global pharmaceutical company. Monsenso’s mobile health solution will be used for real-world data collection across two studies in connection with the launch of a new drug for depression treatment. The studies are expected to start in the first half of 2021 and will run over a three-year period, covering up to 2250 patients and 120 clinicians across Belgium, the Netherlands, the United Kingdom, Switzerland, Italy, Spain, Denmark, Sweden and France.
As a technology leader in mobile health (mHealth) solutions for mental health, Monsenso is ISO 13485 certified. ISO 13485 is the gold standard for medical device companies to ensure the quality, safety and efficacy of products in the medical device field
Monsenso is partnering with pan-European research consortium in the Go Green Routes project supported by Horizon 2020 programme.
Copenhagen, Denmark – 23 July 2020. Monsenso, a technology leader in mobile health (mHealth) solutions for mental health, has received the ISO 27001 re-certification. This is the international standard that describes best practices for an information security management system (ISMS).
Copenhagen Demark – 22 June 2020. The Research Project HedaX, received EUR 16 million from the Danish Innovation Fund to develop a digital platform that can gather and exchange health data. This tool will provide researchers with the basis to offer better, personalised medicine.
Copenhagen, Denmark – 03 June 2020 Monsenso’s offer of DKK 16-20 million new shares have been extremely well received by both professional and private investors, being oversubscribed by 238%.